SCHEMBL304283

SCHEMBL304283

Brc1ccc2c(c1)NCCO2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.62
ALDH1A1 P00352 2/20 0.62
GAA P10253 2/20 0.62
HSD17B10 Q99714 2/20 0.62
PDE3B Q13370 2/20 0.49
PDE3A Q14432 2/20 0.49
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
BLM P54132 1/20 0.48
PRKCI P41743 1/20 0.43
BRD4 O60885 1/20 0.42
FABP6 P51161 1/20 0.40
AHR P35869 3/20 0.39
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
ATM Q13315 1/20 0.39
TRPV1 Q8NER1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30895878 1.00 MAPT (0.62) MAPTALDH1A1GAAHSD17B10PDE3B
Hydrochloric Acid SCHEMBL1820257 0.98 MAPT (0.61) MAPTALDH1A1GAAHSD17B10PDE3B
SCHEMBL20612394 0.89 MAPT (0.50) MAPTALDH1A1GAAHSD17B10PDE3B
SCHEMBL304015 0.85 MAPT (0.49) MAPTALDH1A1GAAHSD17B10PDE3B
SCHEMBL30023822 0.85 MAPT (0.49) MAPTALDH1A1GAAHSD17B10PDE3B
SCHEMBL14129695 0.83 LMNA (0.53) MAPTALDH1A1GAAHSD17B10PDE3B
SCHEMBL8469505 0.80 MAPT (0.42) MAPTALDH1A1GAAHSD17B10PDE3B
SCHEMBL1670103 0.78 SLC5A2 (0.43) MAPTALDH1A1GAAHSD17B10PDE3B
SCHEMBL33867 0.77 ALDH1A1 (0.62) MAPTALDH1A1GAAHSD17B10PDE3B
SCHEMBL2933658 0.77 ALDH1A1 (1.00) MAPTALDH1A1GAAHSD17B10PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747248-A1 COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION Institute of Cancer Research: Royal Cancer Hospital (The) (GB) 2026-05-27 EP disclosed
CN-122094941-A Novel azido formation of 6-hydroxy-benzomorpholine (3, 4-dihydro-2H-1, 4-benzoxazin-6-ol) 2026-05-26 CN disclosed
EP-4721737-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES Scinnohub Pharmaceutical Co., Ltd. (CN) 2026-04-08 EP disclosed
US-12570668-B2 Single molecule compounds providing multi-target inhibition of BTK and other proteins and methods of use thereof SIGNALRX PHARMACEUTICALS, INC. (US) 2026-03-10 US disclosed
EP-4702025-A1 BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-03-04 EP disclosed
US-20260049092-A1 ANTIBACTERIAL COMPOUNDS BLACKSMITH MEDICINES INC (US) 2026-02-19 US disclosed
WO-2025235763-A1 FLUORESCENT PROBES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-11-13 WO disclosed
US-12459921-B2 Isoindoline compound, preparation method, pharmaceutical composition and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2025-11-04 US disclosed
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety CURIS INC (US) 2025-07-17 US disclosed
EP-4568955-A1 ANTIBACTERIAL COMPOUNDS Blacksmith Medicines, Inc. (US) 2025-06-18 EP disclosed
US-6867204-B2 Benzoxazine derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2005-03-15 US disclosed
EP-1506179-A1 BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2005-02-16 EP disclosed
CN-1186328-C Substd. 5-benzyl-2,4-diaminopyrimidines BASLIDE PHARMA AG (CH) 2005-01-26 CN disclosed
EP-1230224-B1 SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES BASILEA PHARMACEUTICA AG (CH) 2004-12-29 EP disclosed
US-6821980-B1 Substituted 5-benzyl-2,4-diaminopyrimidines BASILEA PHARMACEUTICA AG (CH) 2004-11-23 US disclosed
US-20030232825-A1 Benzoxazine derivatives and uses thereof ROCHE PALO ALTO LLC 2003-12-18 US disclosed
WO-2003095434-A1 BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2003-11-20 WO disclosed
CN-1387516-A Substd. 5-benzyl-2,4-diaminopyrimidines BASLIDE PHARMA AG (CH) 2002-12-25 CN disclosed
EP-1230224-A1 SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2002-08-14 EP disclosed
WO-2001032633-A1 SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES BASILEA PHARMACEUTICA AG (CH) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049092-A1 ANTIBACTERIAL COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, FPR1 MAPT 4789/4885ALDH1A1 3250/4885GAA 3838/4885
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety BAZ2A, BAZ2B, PI4KB MAPT 3887/4885ALDH1A1 3415/4885GAA 1190/4885
US-20030232825-A1 Benzoxazine derivatives and uses thereof CYP3A5, CYP4X1, XDH MAPT 4750/4885ALDH1A1 256/4885GAA 1264/4885
US-12459921-B2 Isoindoline compound, preparation method, pharmaceutical composition and use thereof CUL4B, CUL4A, UBQLN1 MAPT 2018/4885ALDH1A1 825/4885GAA 2619/4885
US-12570668-B2 Single molecule compounds providing multi-target inhibition of BTK and other proteins and methods of use thereof BTK, SYK, SRC MAPT 4884/4885ALDH1A1 4743/4885GAA 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.